Majority of U.S. Level III & IV NICUs in 2025 Used Prolacta's 100% Breastmilk-Based Fortifiers & Formulas to Improve Outcomes for Premature Infants

Prolacta Bioscience® is celebrating Prematurity Awareness Month with a significant milestone in neonatal care: In 2025, the ...
WDAF-TV

Alcresta Therapeutics Announces FDA Clearance for Expanded Use of RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Neonates and Infants

WALTHAM, Mass., Nov. 3, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that ...